Edison issues report on BB Biotech (BION)


Werte in diesem Artikel
Aktien

57.60 EUR 1.50 EUR 2.67 %

Edison Investment Research Limited
Edison issues report on BB Biotech (BION)

10-Jun-2025 / 09:06 GMT/BST
The issuer is solely responsible for the content of this announcement.

Werbung


 

London, UK, 10 June 2025

 

Werbung

Edison issues report on BB Biotech (BION)

Edison issues report on BB Biotech (BION).

During 2024 and early this year, the biotech sector began to show signs of a structural recovery, supported by positive clinical data, regulatory approvals, lower interest rates, commercial execution and Johnson & Johnson’s acquisition of Intra-Cellular Therapies, one of BION’s core holdings. However, more recently, the sector has been hit by uncertainties about the macroeconomic outlook, US tariffs and the regulatory policies of the new US administration. This has increased market volatility, especially in the small- and mid-cap companies that BION favours, and the company’s performance has declined accordingly, even though BION’s portfolio holdings are performing well, with several delivering regulatory and clinical milestones. BION’s peers have also struggled in this challenging environment. Yet the news is not all bad. BION’s manager has taken action to protect returns by reducing the number of holdings, increasing the focus on larger-cap names and enhancing risk management. Furthermore, lower valuations have created opportunities for BION to expand exposure to high-quality companies pursuing significant market opportunities via the development of breakthrough therapies. And, most importantly, the biotech sector still has a very positive long-term outlook, with commensurate rewards for those willing to wait out near-term volatility.

Werbung

Click here to read the full report.

All reports published by Edison are available to download free of charge from its website

www.edisongroup.com

Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison’s reports are not solicitations to buy or sell any securities.

For more information, please contact Edison:

enquiries@edisongroup.com

Connect with Edison on:

 

LinkedIn www.linkedin.com/company/edison-group-/

X  www.x.com/edison_inv_res

YouTube www.youtube.com/edisonitv



Dissemination of a CORPORATE NEWS, transmitted by EQS Group.
The issuer is solely responsible for the content of this announcement.


End of Announcement - EQS News Service

2153038  10-Jun-2025 

Aktuelle BB Biotech Aktie News

Werbung

BB Biotech Analysen

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für BB Biotech nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"
DatumRatingAnalyst
21.10.22 BB Biotech Add Baader Bank
27.08.19 BB BIOTECH neutral Independent Research GmbH
30.04.15 BB Biotech accumulate equinet AG
20.04.15 BB Biotech buy Oddo Seydler Bank AG
20.04.15 BB Biotech Verkaufen Independent Research GmbH

Information


Die Handels- und Depotfunktionen in diesem Broker Cockpit werden für Finanzinstrumente von der Finanzen.net Zero GmbH als vertraglich gebundener Vermittler der DonauCapital Wertpapier GmbH (§ 3 Abs. 2 WpIG) bereitgestellt; bei Kryptowerten werden die Handels- und Depotfunktionen in diesem Broker Cockpit ausschließlich von der DonauCapital Wertpapier GmbH bereitgestellt. Die Finanzen.net GmbH stellt ausschließlich den technischen Rahmen bereit und ist in die Wertpapier- und Kryptodienstleistung nicht einbezogen.